- Home
- ELWS vs APM Comparison
ELWS vs APM Comparison
Compare ELWS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- APM
- Stock Information
- Founded
- ELWS 2018
- APM 2010
- Country
- ELWS Japan
- APM United Kingdom
- Employees
- ELWS N/A
- APM N/A
- Industry
- ELWS
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- APM Health Care
- Exchange
- ELWS Nasdaq
- APM Nasdaq
- Market Cap
- ELWS 6.0M
- APM 6.1M
- IPO Year
- ELWS 2023
- APM 2018
- Fundamental
- Price
- ELWS $2.00
- APM $1.07
- Analyst Decision
- ELWS
- APM
- Analyst Count
- ELWS 0
- APM 0
- Target Price
- ELWS N/A
- APM N/A
- AVG Volume (30 Days)
- ELWS 187.8K
- APM 81.2K
- Earning Date
- ELWS 06-17-2025
- APM 06-17-2025
- Dividend Yield
- ELWS N/A
- APM N/A
- EPS Growth
- ELWS N/A
- APM N/A
- EPS
- ELWS N/A
- APM N/A
- Revenue
- ELWS $2,292,406.00
- APM N/A
- Revenue This Year
- ELWS N/A
- APM N/A
- Revenue Next Year
- ELWS N/A
- APM N/A
- P/E Ratio
- ELWS N/A
- APM N/A
- Revenue Growth
- ELWS 404.13
- APM N/A
- 52 Week Low
- ELWS $1.04
- APM $0.46
- 52 Week High
- ELWS $8.68
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- ELWS 50.36
- APM 58.89
- Support Level
- ELWS $1.86
- APM $0.83
- Resistance Level
- ELWS $2.05
- APM $1.35
- Average True Range (ATR)
- ELWS 0.13
- APM 0.12
- MACD
- ELWS 0.00
- APM 0.02
- Stochastic Oscillator
- ELWS 60.58
- APM 46.97
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.